What is the elimination half-life of liothyronine (T3)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Half-Life of Liothyronine

The elimination half-life of liothyronine (T3) is approximately 2.5 days (about 2-2.5 days), though it exhibits biphasic elimination kinetics with a rapid distribution phase of 2.3 hours and a slower terminal elimination phase of approximately 23 hours. 1

Pharmacokinetic Profile

The FDA drug label clearly states that liothyronine has a biological half-life of about 2-1/2 days 1. This relatively short half-life compared to levothyroxine (T4, which has a half-life of approximately 7 days) has important clinical implications:

Key Pharmacokinetic Characteristics:

  • Rapid onset of action: Occurs within a few hours of administration 1
  • Peak effect: Maximum pharmacologic response occurs within 2-3 days 1
  • Absorption: Almost totally absorbed (95% in 4 hours) 1
  • Time to maximum concentration: 1.8 hours 2

Biphasic Elimination Pattern

More recent research has refined our understanding of liothyronine elimination, demonstrating a two-compartment model 2:

  • Fast distribution phase: Half-life of 2.3 ± 0.11 hours
  • Slow elimination phase: Half-life of 22.9 ± 7.7 hours

This biphasic pattern explains why the traditional "2.5 day" half-life represents an average, and why liothyronine's metabolic effects persist for several days following discontinuation despite its rapid initial clearance 1.

Clinical Implications

Advantages of Short Half-Life:

  • Rapid dosage adjustment capability: Allows quick titration when needed 1
  • Easier management of overdosage: Quick cutoff of activity facilitates control if toxicity occurs 1
  • Useful for thyroid scanning procedures: Induction of hypothyroidism is more abrupt and can be of shorter duration 1

Disadvantages:

  • Wide serum T3 swings: The short half-life leads to more pronounced fluctuations in serum T3 levels throughout the day 1
  • Potential for cardiovascular side effects: These fluctuations may increase risk of cardiovascular complications 1
  • Multiple daily dosing considerations: The pharmacokinetics support twice-daily or thrice-daily dosing to maintain stable levels 2

Common Pitfall

Do not assume liothyronine is completely cleared after one half-life. While the drug has rapid distribution and initial clearance, its metabolic effects persist for several days after discontinuation 1. When switching patients from other thyroid preparations to liothyronine, residual effects of the previous medication may persist for the first several weeks of therapy 1.

References

Related Questions

What is the recommended dosing and titration schedule for liothyronine (synthetic liothyronine sodium, T3) in adults, including initial dose, maximum dose, and adjustments for elderly or cardiac patients?
What is the appropriate corrected daily dose of Cytomel (liothyronine) for a patient taking Armour Thyroid (desiccated thyroid) 120 mg with suppressed TSH and free T4, and how should the dose be divided?
What is the appropriate liothyronine (T3) dosage for thyroid suppression in adults?
Is Cytomel (liothyronine) removed by dialysis, and does a patient on dialysis require a dose reduction?
Should Cytomel (liothyronine) be taken on an empty stomach?
What is the appropriate antibiotic regimen and management for Actinomyces bacteremia?
I woke up with lateral tongue lacerations; could this indicate a generalized tonic‑clonic seizure and should I seek emergency evaluation?
What are the recommended fish‑oil (EPA + DHA) dosing guidelines for children aged 2–5, 6–12, and 13–18 years?
Is clonazepam appropriate for use in children and adolescents, and what are the recommended age limits and dosing guidelines?
In a patient with acute coronary syndrome and atrial fibrillation requiring oral anticoagulation, should aspirin or clopidogrel be prioritized as the antiplatelet therapy?
For a patient with benign prostatic hyperplasia and urinary symptoms, how should I choose between alfuzosin (Xatral) and daily tadalafil, including dosing, renal dose adjustments, and safety concerns about combining the two drugs?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.